NCT04843930

Improving Cognitive Health in COVID-19 Survivors

Improving Cognitive Health in COVID-19 Survivors Through Digital Therapeutics

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: Weill Medical College of Cornell University · Academic / Other
• Sex: All
• Age: 18 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to investigate the efficacy of AKL-T01, a remotely-delivered digital cognitive intervention, relative to a waitlist control in improving cognitive functioning in COVID-19 survivors.

Detailed description

Emerging evidence suggests a subgroup of survivors of COVID- 19 have residual difficulties with cognition and daily functioning. These deficits are pronounced in cognitive domains including attention, learning and executive skills, and may continue to impact quality of life after recovery from other COVID-19 symptoms. This study aims to investigate the efficacy of AKL-T01 (Akili Interactive), a remotely-delivered digital cognitive intervention, in targeting and improving cognition and functional outcomes in individuals recovering from COVID-19. The efficacy of the AKL-T01 intervention will be measured relative to a waitlist control group.

Conditions

• Cognitive Dysfunction
• Covid19

Interventions

Type	Name	Description
DEVICE	AKL-T01	AKL-T01 will be administered as a 6-week intervention. It is an algorithmically delivered iPad-based video game designed to improve cognitive health by targeting attention and attentional control processes.

Timeline

• Start date: 2021-07-13
• Primary completion: 2023-02-06
• Completion: 2023-04-26
• First posted: 2021-04-14
• Last updated: 2024-02-29
• Results posted: 2024-02-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study